Skip to main content
PHARMX TECHNOLOGIES LIMITED logo

PHARMX TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · PHX ISIN · AU0000298762 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2026-05-04 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PHX

About PHARMX TECHNOLOGIES LIMITED

https://pharmx.com.au/

PharmX Technologies Limited specializes in providing digital infrastructure for the pharmaceutical supply chain. Its primary offering is the PharmX platform, a centralized electronic data interchange (EDI) gateway that facilitates seamless transactions between retail pharmacies and their suppliers. The platform enables the automated exchange of purchase orders, invoices, and credit notes, streamlining procurement processes and reducing manual data entry errors. By integrating with a wide range of pharmacy point-of-sale (POS) systems and wholesaler platforms, PharmX provides a standardized communication layer that enhances operational efficiency across the sector. The company focuses on maintaining secure, reliable, and scalable technology solutions to support the high-volume transactional needs of the retail pharmacy market.

Recent filings

Filing Released Lang Actions
Q3 Investor Update FY2026 6 pages 431.1KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 5 May 2026 titled 'Pharmx Q3 Investor Update FY2026'. It provides a quarterly update covering the period to 31 March 2026, including strategic highlights, commercial progress, and financial metrics related to the company's marketplace growth and strategic alliance. The content is focused on business updates and performance metrics for a quarter, typical of an interim or quarterly report. The document length is 11,370 characters, which is substantial and contains detailed financial and operational data for the quarter. There is no indication that this is a full annual report or an earnings release with only key highlights. It is not a call transcript, audit report, or other specific filing types. Therefore, the document fits best as an Interim / Quarterly Report (IR).
2026-05-04 English
Director Appointment 2 pages 796.0KB
Board/Management Information Classification · 100% confidence The document is an announcement dated 13 March 2026 from Pharmx Technologies Limited regarding the appointment of Mr. Mark Conway as a Non-Executive Director. It details his background, experience, and the strategic rationale for his appointment. There is no financial data, no mention of a report or meeting materials, no voting results, no legal proceedings, no capital changes, and no earnings information. The content clearly relates to a change in the company's board of directors. The document length is 3523 characters, which is relatively short but contains substantive information about management changes rather than a mere announcement of a report. Therefore, the appropriate classification is Board/Management Information (MANG).
2026-03-12 English
Initial Director's Interest Notice - M Conway 2 pages 252.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, with no securities held. This is a report of personal share transactions or interests by a company director. The document length is short and focused solely on director's interests, matching the definition of Director's Dealing filings. Therefore, the appropriate classification is DIRS (Director's Dealing).
2026-03-12 English
Becoming a substantial holder 29 pages 763.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder under the Corporations Act 2001, detailing a substantial shareholding acquisition by CW Retail Holdings Pty Ltd and related entities in Pharmx Technologies Limited. It includes voting power details, relevant interests, consideration paid, and annexures with related agreements. This type of filing is a notification of a major shareholding change, specifically the initial substantial holder notice, which aligns with the category for Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory disclosure of shareholding changes.
2026-03-11 English
Application for quotation of securities - PHX 6 pages 18.2KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the number and type of securities to be quoted, issue dates, and other issuance details. This type of document is a formal announcement related to the listing or quotation of securities following a prior issuance announcement (Appendix 3B). It is not a financial report, earnings release, or management discussion. It is specifically related to capital changes and securities quotation. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2026-02-25 English
Cleansing Notice 2 pages 164.5KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement titled 'Cleansing Notice under Section 708A(5)(e) of the Corporations Act'. It details the issuance of new shares by Pharmx Technologies Limited to a related party under a strategic alliance, referencing compliance with specific sections of the Corporations Act. The content focuses on regulatory compliance related to a share issue and does not contain financial statements, management discussion, or detailed financial results. The document length is 2669 characters, which is relatively short and primarily serves as a regulatory disclosure about the share issuance without financial data or report content. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), as it announces a new share issue and related compliance notice.
2026-02-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.